LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

Home・Akcijų sąrašas・Compugen Ltd

Compugen Ltd

Uždarymo kaina

2.02 -0.49

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

Max

2.02

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-65M -7.7M
Pardavimai	-65M 2.2M
P/E Sektoriaus vid.	5.368 49.052
Pelnas, tenkantis vienai akcijai	-0.08
Pelno marža	-352.436
Darbuotojai	75
EBITDA	-64M -7.7M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+145.1% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-77M 193M
Ankstesnė atidarymo kaina	2.51
Ankstesnė uždarymo kaina	2.02

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-13 23:52; UTC

China's House Price Index YoY release on June 16, 2026, faces cautious market sentiment amid ongoing declines and geopolitical tensions.

2026-06-13 23:51; UTC

Correlated Moves

Bitcoin has advanced since Friday, reflecting positive sentiment in the cryptocurrency market. The asset remains below its 20-day moving average and near its one-month range low.

2026-06-13 23:41; UTC

U.S. Stocks Surge on SpaceX IPO and Optimism Over U.S.-Iran Peace Talks, While Traders Anticipate Fed's Interest Rate Decision Amid Inflation Concerns.

2026-06-13 23:41; UTC

U.S. Stocks Surge on Peace Deal Optimism, Fed Expected to Hold Rates Amid Geopolitical Tensions and Key Economic Data Ahead.

2026-06-13 23:41; UTC

U.S. Stocks Surge on Peace Deal Optimism and Global Mineral Economy Shift Ahead of Steady Fed Rate Decision.

2026-06-13 23:41; UTC

U.S. Stocks Surge on SpaceX IPO and Peace Deal Hopes, While Investors Brace for Key Economic Data and Fed Rate Decision.

2026-06-13 23:41; UTC

Philadelphia Fed Manufacturing Index Release on June 18, 2026, Anticipates Growth Amid Mixed Economic Sentiment and Inflation Concerns.

2026-06-13 23:31; UTC

U.S. Industrial Production MoM data for May 2026 expected to rise by 0.2% amid cautious optimism following April's strong performance of 0.7%.

2026-06-13 23:21; UTC

U.S. Retail Sales MoM Report on June 17 Expected to Show Modest 0.5% Increase Amid Geopolitical Tensions and Consumer Spending Optimism

2026-06-13 23:21; UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in May Amid Cautious Consumer Sentiment and Economic Resilience

2026-06-13 23:21; UTC

Canada's New Housing Price Index set for June 17 release, with a forecasted slight decline amid ongoing affordability challenges and government announcements.

2026-06-13 23:11; UTC

Market Anticipates U.S. Building Permits Data Release Amid Cautious Optimism and Economic Concerns on June 16, 2026.

2026-06-13 23:02; UTC

India's RBI to release monetary policy meeting minutes amid lower-than-expected CPI inflation and rising food costs, influencing future interest rate decisions.

2026-06-13 23:02; UTC

Upcoming U.S. Housing Starts Data Release on June 16, 2026 Expected to Reflect Economic Conditions Amid Government Initiatives and Rising Demand.

2026-06-13 23:02; UTC

Investors Anticipate Further Increases in U.S. Export Prices Ahead of June 16 Release Amid Geopolitical Developments

2026-06-13 23:02; UTC

U.S. Housing Starts Expected to Reach 1.44 Million Units in May Amid Mixed Trends and Policy Discussions Ahead of June 16 Release

2026-06-13 23:02; UTC

U.S. Import Prices Report on June 16 Expected to Show 0.9% Increase Amid Geopolitical Optimism and Inflation Concerns

2026-06-13 23:02; UTC

Market Anticipates 1.41 Million Building Permits in May 2026 Amidst Cautious Optimism for Housing Sector Recovery.

2026-06-13 23:01; UTC

Macro News

DAX 30 Index rises in after-market trading amid optimism for a U.S.-Iran peace deal and President Trump's announcement on the Strait of Hormuz.

2026-06-13 22:51; UTC

Japan's Year-on-Year Inflation Rate Release on June 18 Expected to Show Stability Amid Mixed Economic Signals and Global Influences.

2026-06-13 22:51; UTC

Japan's Core Inflation Rate Expected to Hold at 1.4% Amid Cautious Market Sentiment and BOJ Policy Considerations

2026-06-13 22:41; UTC

Market anticipates June 15 release of NY Empire State Manufacturing Index at 13.2, signaling cautious optimism amid inflation concerns and geopolitical developments.

2026-06-13 22:41; UTC

Japan's Machinery Orders Expected to Rise 0.9% in April Amidst Mixed Economic Signals and Improving Investor Confidence

2026-06-13 22:41; UTC

Japan's Exports Expected to Rise 0.162% YoY in June Amid Positive Economic Sentiment and Geopolitical Easing, Despite Competition from China

2026-06-13 22:41; UTC

Mortgage Rates Set to Rise Amid Geopolitical Tensions and Economic Uncertainty, with Upcoming MBA Report Expected on June 17.

2026-06-13 22:32; UTC

UK Consumer Confidence Index for June 2026 Forecasted at -23 Amid Ongoing Inflation and Economic Uncertainty

2026-06-13 22:32; UTC

Canada's May 2026 Housing Starts Data Set for Release, Forecasted at 255K Units Amid Optimistic Market Sentiment and Government Initiatives.

2026-06-13 22:32; UTC

Brazil's Central Bank to Provide Key Interest Rate Insights on June 15, Amidst Cautious Market Sentiment and Global Economic Influences.

2026-06-13 22:32; UTC

Japan's trade deficit forecasted at -564.6 billion yen amid high import costs, but market optimism rises following easing U.S.-Iran tensions and strong Asian stock performance.

2026-06-13 22:32; UTC

Brazil's Retail Sales Report on June 16 Expected to Show Resilience Amid Mixed Economic Signals

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

145.1% į viršų

12 mėnesių prognozė

Vidutinis 5 USD 145.1%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Compugen Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.